Recent News

• 08.18.2025 - European Commission Grants Approval of OGSIVEO® (nirogacestat) for the Treatment of Adults with Desmoid Tumors
• 08.18.2025 - European Commission Grants Approval of OGSIVEO® (nirogacestat) for the Treatment of Adults with Desmoid Tumors
• 08.18.2025 - European Commission Grants Approval of OGSIVEO® (nirogacestat) for the Treatment of Adults with Desmoid Tumors
• 08.18.2025 - European Commission Grants Approval of OGSIVEO® (nirogacestat) for the Treatment of Adults with Desmoid Tumors
• 07.18.2025 - European Commission Grants Conditional Approval of EZMEKLY® (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN
• 07.18.2025 - European Commission Grants Conditional Approval of EZMEKLY® (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN
• 07.18.2025 - European Commission Grants Conditional Approval of EZMEKLY® (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN
• 07.18.2025 - European Commission Grants Conditional Approval of EZMEKLY® (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN

Recent Filings

• 08.13.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 08.08.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 07.11.2025 - 15-12G Securities registration termination [Section 12(g)]
• 07.07.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 07.02.2025 - 4 Statement of changes in beneficial ownership of securities
• 07.02.2025 - 4 Statement of changes in beneficial ownership of securities
• 07.02.2025 - 4 Statement of changes in beneficial ownership of securities
• 07.02.2025 - 4 Statement of changes in beneficial ownership of securities
• 07.02.2025 - 4 Statement of changes in beneficial ownership of securities
• 07.02.2025 - 4 Statement of changes in beneficial ownership of securities